Allos Therapeutics, Inc.
11080 Circlepoint Road
Suite 200
Westminster,
CO 80020
Telefone: 303-426-6262
Fax: 303-412-9160
Web Site: http://www.allos.com
| Allos Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing small molecule drugs for the treatment of cancer. Its lead product candidate includes Pralatrexate, an antifolate under Phase II trial, which accumulates preferentially in cancer cells and treats patients with relapsed or refractory peripheral T-cell lymphoma. The company also offers RH1, a small molecule chemotherapeutic agent, which is under Phase I trial to treat patients with advanced solid tumors and non-Hodgkins lymphoma. In addition, it is evaluating Pralatrexate in various Phases for the treatment of non-Hodgkin's Lymphoma and Hodgkin's disease, cutaneous T-cell lymphoma, non-small cell lung cancer, bladder cancer, and other solid tumor indications. The company was formerly known as HemoTech Sciences, Inc. and changed its name to Allos Therapeutics, Inc. in October 1994. Allos Therapeutics, Inc. was founded in 1992 and is headquartered in Westminster, Colorado. |
|
| Principais estatísticas | Mais da Reuters
Descrição expandida da empresa |
| |
| | Pago | Exercido | Mr. Paul L. Berns , 43
Chief Exec. Officer, Pres and Exec. Director |
$
795.00K | N/D | Mr. David C. Clark , 41
Chief Financial Officer, Principal Accounting Officer, VP of Fin., Treasurer and Assistant Sec. |
$
259.00K | N/D | Mr. Marc H. Graboyes , 40
Sr. VP, Sec. and Gen. Counsel |
$
385.00K | N/D | Mr. James V. Caruso , 51
Chief Commercial Officer and Exec. VP |
$
564.00K | N/D | Mr. Bruce K. Bennett Jr., 58
VP of Pharmaceutical Operations |
N/D
| N/D |
|
|
|
Somas desde
31-Dec-08
e valores de compensação são para o ano fiscal que termina nesta data. "Pago" é salário, bônus, etc. "Exercício" é o valor de ações exercidas durante o ano fiscal.
| |
|
Ajuda
0.07 (1.02%) 
Perfil
A Reuters oferece mais 
